Key points

  • Antonio Gracias, a SpaceX director and founder of Valor Equity Partners, put $25 million into the company behind MDMA therapy for PTSD, The Wall Street Journal reported.
  • That company, now Resilient Pharmaceuticals, is private, so none of the money is visible in any Form 4.
  • Among the listed psychedelics names one cluster stands out: two Cybin (HELP) officers bought 385,000 shares in four open-market purchases worth $4.55 million.

Elon Musk's inner circle is funding the effort to bring psychedelics into mainstream medicine, The Wall Street Journal reported on September 5. Antonio Gracias, who sits on the SpaceX board and runs Chicago's Valor Equity Partners, contributed $25 million of a roughly $50 million recapitalisation of Lykos Therapeutics, alongside British investor Chris Hohn.

Lykos needed the money after the FDA rejected its MDMA-assisted therapy for post-traumatic stress disorder in August 2024 and asked for an additional Phase 3 trial. The company was renamed Resilient Pharmaceuticals, moved to Chicago and refiled in August 2026 — offering a 32-person Phase 1 safety study and an audit of the original trial data rather than the new Phase 3 the agency requested.

Gracias is not the only Musk director involved. Steve Jurvetson and his wife Genevieve were $1 million-plus donors to MAPS, the nonprofit that ran the original trials, and Dr. Bronner's chief executive David Bronner, the Steven and Alexandra Cohen Foundation and Joby Pritzker have all funded the field. Gracias separately endowed a Harvard program studying psychedelics with $16 million in 2023.

Washington has moved toward the same door. President Trump's April 18 executive order routes psychedelics holding breakthrough designation into the FDA's National Priority Voucher program, which targets a one-to-two-month review instead of the usual six to twelve, and the FDA holds a public hearing on the drugs on September 14.

None of that spending reaches insider data, because Resilient is private and private companies file no Form 4. In the Form 4 record reviewed by InsiderBuying.com the listed names mostly show the opposite of conviction: at AtaiBeckley (ATAI), whose shareholders approved a cash takeover by Eli Lilly on September 8, every filing this year is an option exercise followed by a sale, and at Definium Therapeutics (DFTX), formerly MindMed, chief executive Robert Barrow sold $721,733 of stock on September 3.

Cybin, which now trades as HELP, is the exception. Executive chair Eric So bought 95,000 shares on September 1 and 100,000 on September 4; chief growth officer Paul Glavine bought 90,000 on August 31 and 100,000 on September 3 — four open-market purchases, 385,000 shares, $4.55 million, paid for with personal funds. Both men followed with Schedule 13D filings on September 9, and So's puts him at 5.8% of the class.

What to watch: the September 14 hearing is a public meeting, not an advisory committee, so it carries no vote and no approval decision. The sharper test is whether Resilient's refiling draws a review date without the Phase 3 the FDA asked for — and whether Cybin's officers keep buying above the $11.59 to $12.09 they have paid so far.

Track the filings as they land on HELP, or follow every open-market purchase as it files with InsiderBuying Premium.